Besides the therapeutic relevance of PARP inhibitors, non-invasive imaging of PARP with the aid of positron emission tomography (PET) possesses the potential to predict tumor malignancy since elevated PARP1 expression is associated with poor prognosis and lower survival rates in breast cancer and leukemia [15, 16]. Here, PARP1 is linked to leukemia.